Newcastle Disease Virus: Virus Particle and RNA Synthesis in Different Host Cells and at Different Temperatures

Huppert, J.; Gresland, Luce; Rosenbergova, Martha

doi:10.1099/0022-1317-22-1-129

Cited by 8 publications

(4 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One of the first events that occurs after infecting a cancer cell is a rapid rate of virus replication, with progeny virions detectable as early as three hours post infection [24]. Neighboring tumor cells are infected through the release of progeny virions, as well as, through syncytia formation [25].…”

Section: Preclinical Experiencementioning

confidence: 99%

Phase 1 Clinical Experience Using Intravenous Administration of PV701, an Oncolytic Newcastle Disease Virus

Lorence¹,

Roberts²,

O'Neil³

et al. 2007

CCDT

View full text Add to dashboard Cite

PV701 is a naturally-attenuated, non-recombinant, oncolytic strain of Newcastle disease virus that displays preclinical intravenous (IV) efficacy. PV701 is selective at killing human cancer cells versus normal human cells based on tumor specific defects in the interferon (IFN)-mediated antiviral response. This oncolytic virus displays a broad spectrum of antitumor activity in vitro and in vivo. Preclinical models successfully predicted key clinical parameters including the mechanism of toxicity, two complementary strategies (desensitization and slow infusion) to reduce toxicity, and the starting dose for phase 1 trials. In three phase 1 trials of 114 patients using IV administration of PV701, Wellstat Biologics Corporation has evaluated the effects of dose, schedule, and infusion rate for PV701. Three general classes of side effects were seen: flu-like symptoms; tumor-site-specific adverse events (AEs); and infusion reactions. The first PV701 dose desensitized the patient to the side effects of further doses, allowing a marked increase in the maximum tolerated dose for subsequent doses compared to the first dose. Tumor responses were first noted at the higher doses achieved using desensitization. In the most recent phase 1 trial of 19 patients at Hamilton, Ontario, that employed desensitization, high repeat doses, and a slower infusion rate (Hamilton Regimen), there were six responses (4 major; 2 minor) and a total of six patients with survival for at least 2 years. In addition, patient tolerability improved using the Hamilton Regimen compared to IV bolus dosing used previously. Phase 2 studies of this novel biologic agent are about to begin.

show abstract

Section: Preclinical Experiencementioning

confidence: 99%

Phase 1 Clinical Experience Using Intravenous Administration of PV701, an Oncolytic Newcastle Disease Virus

Lorence¹,

Roberts²,

O'Neil³

et al. 2007

CCDT

View full text Add to dashboard Cite

show abstract

“…Cell sheets were incubated for 10 min at room temperature with TNE buffer, pH 8.4, adjusted to 1% sodium dodecyl sulfate (SDS) and 1% 8-mercaptoethanol. RNA was then extracted twice with phenol buffered in NTE, pH 8.4, and 0.5% (-mercaptoethanol, according to a previously described technique (2,9). A final extraction was performed with phenol buffered in NTE, pH 7.4.…”

Section: Methodsmentioning

confidence: 99%

Rifampin-susceptible mutant of vesicular stomatitis virus: protein and RNA synthesis

Moreau¹,

Sanzey²

1977

J Virol

View full text Add to dashboard Cite

A rifampin-susceptible strain (VSV Rif+) was selected from the wild vesicular stomatitis virus (VSV) population unsusceptible to rifampin. The VSV Rif+ was blocked in its intracellular replication in the presence of rifampin. In cells, rifampin affected primarily VSV Rif+ transcription, but to a different extent than in a cell-free system. In addition, a decrease in the amount of VSV Rif+ protein M was detected, linked to a stimulation of protein NS. In the absence of rifampin, protein M, although synthesized, was not immediately incorporated into the cell membrane. An interpretation of these observations is proposed.

show abstract

“…Chick embryo cells (CEC) were obtained as described by Huppert et al (1974). Virus haemagglutination.…”

Section: Introductionmentioning

confidence: 99%

“…Newcastle disease virus, Hertfordshire strain, was propagated in embryonated eggs; the stock used had an IDs0 titre of IO912/ml and was prepared as described by Huppert, Gresland & Rosenbergova (1974).…”

Section: Introductionmentioning

confidence: 99%

Induction of Virus Ribonucleic Acids in Non-permissive MSV-IF + Cells Infected with NDV

Dubois

Huppert²

1974

Journal of General Virology

Self Cite

View full text Add to dashboard Cite

SUMMARYMouse cells (MSV-IF+) are completely non-permissive to NDV; however, they produce interferon when NDV is used as an inducer. Eight h after infection these cells synthesize a virus 'minus' strand RNA which anneals to the extent of 57 to 97 % with virus 'plus' strand RNA. This synthesis disappears gradually up to 48 h after infection, and is not modified by the incubation temperature (37 °C or 40 °C) of the infected cells.

show abstract

Newcastle Disease Virus: Virus Particle and RNA Synthesis in Different Host Cells and at Different Temperatures

Cited by 8 publications

References 21 publications

Phase 1 Clinical Experience Using Intravenous Administration of PV701, an Oncolytic Newcastle Disease Virus

Phase 1 Clinical Experience Using Intravenous Administration of PV701, an Oncolytic Newcastle Disease Virus

Rifampin-susceptible mutant of vesicular stomatitis virus: protein and RNA synthesis

Induction of Virus Ribonucleic Acids in Non-permissive MSV-IF + Cells Infected with NDV

Contact Info

Product

Resources

About